These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094 [TBL] [Abstract][Full Text] [Related]
7. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Hack SP; Zhu AX; Wang Y Front Immunol; 2020; 11():598877. PubMed ID: 33250900 [TBL] [Abstract][Full Text] [Related]
8. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139 [TBL] [Abstract][Full Text] [Related]
9. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Chiang IT; Lee YH; Tan ZL; Hsu FT; Tu HF Biomed Pharmacother; 2022 Mar; 147():112661. PubMed ID: 35092865 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study. Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523 [TBL] [Abstract][Full Text] [Related]
11. EGFR mutations induce the suppression of CD8 Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699 [TBL] [Abstract][Full Text] [Related]
12. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553 [TBL] [Abstract][Full Text] [Related]
17. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362 [TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer. Shin HS; Choi J; Lee J; Lee SY Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693 [TBL] [Abstract][Full Text] [Related]
19. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213 [TBL] [Abstract][Full Text] [Related]
20. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]